author-photo

Ulf Madsbu

Oslo University Hospital

12

Papers

67

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.

2020 Blood Advances
Show All
- Source
- Cite
- Save
Citations (3)
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma.

2020 European Journal of Nuclear Medicine and Molecular Imaging
Show All
- Source
- Cite
- Save
Citations (2)
LYMRIT 37-01: UPDATED RESULTS OF A PHASE I/II STUDY OF 177 LU-LILOTOMAB SATETRAXETAN, A NOVEL CD37-TARGETED ANTIBODY- RADIONUCLIDE-CONJUGATE IN RELAPSED NHL PATIENTS

2017 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (4)
A HIGHER AMOUNT OF LILOTOMAB PRE-DOSING INCREASES THE ACTIVITY-ADJUSTED AUC AND HAS A PROTECTIVE EFFECT AGAINST MYELOSUPPRESSION OF LUTETIUM (177LU)-LILOTOMAB SATETRAXETAN IN INDOLENT NHL PATIENTS

2017 Haematologica
Show All
- Source
- Cite
- Save
Citations (2)
Abstract LB-252: Efficacy and safety results of Betalutin® (177Lu-DOTA-HH1) in a phase I/II study of patients with non-hodgkin B-cell lymphoma (NHL)

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
177lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL), Phase 1/2 Safety and Efficacy Data from Four Different Pre-Dosing Regimens

2016 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Efficacy and Safety Results of a Phase 1 Study of 177 lu-DOTA-HH1 (Betalutin®) with and without HH1 Pre-Dosing for Patients with Relapsed CD37+ Non-Hodgkin B Cell Lymphoma (NHL)

2015 Blood
Show All
- Source
- Cite
- Save
Citations (1)
A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma

2014 Blood
Show All
- Source
- Cite
- Save
Citations (3)
A Novel Cancer Vaccine Strategy In Previously Untreated Patients with Stage III/IV Follicular Lymphoma Generates Tumor-Reactive T Cells and Clinical Response

2010 Blood
Show All
- Source
- Cite
- Save
Citations (0)